CTOs on the Move

CG Pharmaceuitcals

www.cgpharma.com

 
CG Pharmaceuitcals is a Emeryville, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.cgpharma.com
  • 5858 Horton St Ste 265
    Emeryville, CA USA 94608
  • Phone: 510.594.8201

Executives

Name Title Contact Details

Similar Companies

Ignyta

Ignyta, located in San Diego, California, is a biotechnology company developing precision medicine with integrated Rx/Dx solutions for cancer patients. Its goal is to discover and develop revolutionary new drugs that target activated genes in cancer cells for the customized treatment of cancer patients. The company's present focus is on the development of RXDX-101, its proprietary oral tyrosine kinase inhibitor that targets solid tumor indications, and advancing its novel Spark discovery programs that leverage its proprietary cancer genomic and epigenomic knowledge bases

ChemNavigator

At ChemNavigator we help research organizations identify and procure the chemistry they need for drug discovery and agrochemical research. We serve researchers in medicinal, computational, and synthetic chemistry as well as chemical procurement

Stericide

Stericide is a Lake Forest, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DNA SOLUTIONS

DNA SOLUTIONS is a Miami, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Telo Genomics

Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team’s considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease-associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been substantiated in over 150 peer reviewed publications and in 25 clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer’s disease. Our lead application, Telo-MM is being developed to provide important, actionable information to medical professionals in the treatment of Multiple Myeloma, a deadly form of blood cancer.